Overview
ElmediX operates in the medical equipment manufacturing sector with a mission centered on increasing patient survival and quality of life.
Leadership & org chart
In the news
- Today is Dag tegen Kanker. At ElmediX, it is our mission every day. Today, we stand in solidarity with everyone affected by cancer — patients, their families, and those who support them. At ElmediX, we are committed to developing new therapeutic options for patients facing some of the deadliest forms of cancer. Through TempoCure®, our whole-body hyperthermia technology, we aim to improve treatment outcomes, with a particular focus on pancreatic cancer, one of the most challenging cancers to treat. For us, fighting cancer is
- We are excited to welcome Nicolas Douillié, our new Junior Medical Device Engineer, to ElmediX! As we prepare for the launch of our MATTERS-2 clinical trial and strengthen our technical task force supporting its execution, Nicolas will play an important role in the clinical use of TempoCure and in supporting our participating sites. Welcome aboard, Nicolas! We are very happy to have you onboard for this exciting next phase of ElmediX. #ElmediX #TempoCure #MATTERS2 #ClinicalTrials #MedTech
- At ElmediX, innovation is built on a deliberate duality: medicine and engineering. At #ESMO Gastrointestinal Cancers Congress 2026, our co-founders John-Paul Bogers and Johan Van den Bossche represented these two souls of medical device development—the clinical and the technical, the biological and the systemic. This interplay is not conceptual; it is operational. The MD perspective anchors us in disease biology, patient need, and clinical reality. The engineering perspective translates that understanding into robust, scalable,
- ElmediX is hiring! We are looking for a motivated Junior Medical Device Engineer to join our technical team and support the development and clinical testing of TempoCure. This is a hands-on role at the intersection of engineering, medical technology, and clinical research. Interested in contributing to an innovative clinical trial program? Please see our vacancy here on LinkedIn. https://lnkd.in/eZi8XVbw
- Last week, #ElmediX had the pleasure of welcoming investors, partners, and collaborators to our investor event in support of our Series A fundraising. Set in the stunning surroundings of Sint-Michiel Castle, the evening was opened by our CEO, John-Paul Bogers, followed by our CMO, Marc Peeters, who presented an overview of the upcoming #MATTERS-2 clinical study in metastatic pancreatic cancer. Christof Debèfve and Merel Verschueren then presented the role of XPER Research as our dedicated CRO. The evening concluded with our
- June marks an important milestone for ElmediX: we have submitted the regulatory requests to initiate #MATTERS-2, the randomized controlled clinical trial designed to evaluate the efficacy of whole-body hyperthermia, using #TempoCure, in combination with systemic therapy, in patients with metastatic pancreatic cancer. #MATTERS-2 represents our commitment to taking this approach into a controlled clinical setting and investigating its potential role for patients facing a disease with significant unmet medical need. This milestone has
Alumni
Luigi BrancatoR&D Engineer
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.